Home > Boards > US OTC > Delisted >

Vicor Technologies, Inc. fka VCRTQ

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/5/2016 10:12:21 PM - Followers: 16 - Board type: Free - Posts Today: 0

Vicor Technologies, Inc. (OTCQB & OTCBB: VCRT) is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i® nonlinear algorithm. Physician use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.


Diagnostics that enable inexpensive, accurate, and early identification of disease states in at-risk populations prior to costly treatments for advanced disease or resulting from inaccurate identification are garnering increased attention in the current health care reform environment.  These populations are significant:

  • 23.6 million diabetics
  • 15 million at-risk cardiac patients
  • 38 million trauma incidents

Vicor's diagnostics are being developed to address those needs easily, accurately, and inexpensively. Vicor's PD2i Analyzer™ has FDA 510(k) marketing clearance to both measure heart rate variability (HRV) for physician-determined use and be used specifically in cardiovascular disease testing. Physicians who have purchased the PD2i Analyzer™ are largely using it to test their diabetic patients for autonomic nervous system (ANS) dysfunction, also known as diabetic autonomic neuropathy or DAN. Cardiologists are using it to test their cardiovascular disease patients to risk stratify them for cardiac death resulting from arrhythmia or congestive heart failure. Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer™ to measure HRV to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.




Vicor's PD2i® Nonlinear Algorithm - A Revolutionary New Vital Sign

Vicor's point correlation dimension (PD2i®) nonlinear algorithm is at the heart of Vicor Technologies' PD2i Analyzer™, which is sometimes referred to as the PD2i CA™ (Cardiac Analyzer), and PD2i VS™.


Decoding The Interaction of Brain and Heart
We know intuitively that the brain influences the heart. Vicor has taken this understanding a step further. Through years of research and experimentation, Vicor Technologies' Chief Scientist Dr. James Skinner was able to determine that while cardiac arrest occurs in the heart, it is initiated by the brain. Dr. Skinner developed the PD2i® nonlinear algorithm, which examines a sequence of heartbeats to detect the subtle tell-tale patterns that reveal whether the brain's interaction with the heart is healthy or is putting the patient at high risk of cardiac death.  Conventional diagnostics, which only evaluate the heart, are of limited use in predicting cardiac death. Further, current guidelines for implantable cardioverter defibrillators (ICDs) are inadequate and lead to implantations in many people who don't need them. Studies show that, at present, 20 ICDs must be implanted to save a single life. Of even greater concern, nearly 80 percent of those who do die from cardiac death would not even qualify for implantation under current criteria. Clearly, a more accurately predictive diagnostic is greatly needed.  Vicor's PD2i® test may be that diagnostic.A case in point: Both patients below meet current implantation guidelines. But which one will die without an ICD?

The ECG for Patient 032 (above left) is normal according to current interpretations. Conversely, the ECG for Patient 160 (above right) is grossly abnormal by current interpretations. Relying on the above tracings, a physician might well recommend "watchful waiting" for Patient 032 and an ICD for Patient 160.  In contrast, the PD2i® test is able to correctly indicate Patient 032′s imminent cardiac death and Patient 160′s lack of risk:

Further, the PD2i® would predict that Patient 032 was in need of an ICD, and Patient 160 required no intervention. In summary, the PD2i® nonlinear algorithm, as shown by these examples, should reduce both false positives and false negatives, indications for who does and who does not need an ICD.

Unprecedented Predictive Potential
Published clinical trial data shows the PD2i® nonlinear algorithm is a highly accurate predictor of cardiac death, with a sensitivity approaching 100 percent and a specificity of approximately 86 percent. All that is required to conduct the analysis is an ECG of a thousand heartbeats (requiring less than 20 minutes). The PD2i® typically uses recordings made at rest and does not require stress-testing or any active participation from the patient. The PD2i® test is relatively impervious to data non-stationarities and artifacts, setting it apart from other measures, and its sensitivity is unparalleled.

Current Implementations of the PD2i® Nonlinear Algorithm
Vicor received FDA 510 (k) marketing clearance for the PD2i Analyzer™, on December 29, 2008. The PD2i Analyzer™ measures heart rate variability (HRV) in patients at rest, and in response to paced respiration and controlled exercise, and is expected to be capable of identifying autonomic nervous system (ANS) dysfunction earlier than conventional means.  During 2010, Vicor Technologies expects to launch two additional diagnostics: the   PD2i CA™   , which identifies cardiovascular disease patients at risk of cardiac death resulting from arrhythmia or pump failure, and the PD2i VS, which facilitates triage of seriously injured combat and civilian trauma victims.

An Advance Over Conventional Diagnostics
Vicor's PD2i CA™ -based diagnostics offer serveral potential advantages over other measures.  They:

  • are more predictive than competing tests
  • are non-invasive
  • may be performed by a nurse or technician
  • are done at rest
  • use inexpensive, non-proprietary ECG electrodes
  • provide results in less than 20 minutes
  • are easy to use
  • yield a simple binary result
  • are compact and portable
  • are forgiving of data issues plaguing other diagnostics and are not derailed by irregular or ectopic beats
  • may be performed on patients taking beta-blockers            

Learn Even More About Vicors PD2i® Technology by calling Vicor at 877.528.7324!

Vicor Technologies, Inc. Company Information & Financials

Contact Information:

Vicor Technologies, Inc.
2200 Corporae Blvd., N.W.
Suite 401
Boca Raton, Florida 33431
561.995.7313 (Local Telephone)
877.528.7324 (Toll-Free)

Business Description:

Vicor Technologies, Inc. (OTCBB: VCRT) creates innovative, non-invasive diagnostics based on its patented PD2i® nonlinear algorithm, a new vital sign which accurately determines the likelihood of pathological events in specific populations.

Financial Reporting/Disclosure:
Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Not Available
Regulatory Agency Not Available
CIK 0001335104
Fiscal Year End 12/31
OTC Market Tier OTCQB

Profile Data: 
SIC - Industry Classification 3841 - Surgical and medical instruments
Business Status Development Stage Company a/o Mar 31, 2007
Incorporated In: DE, USA
Year of Inc. 2005
Employees Not Available

Corporate Officers:
James E. Skinner Interim Chairman & CEO
Richard M. Cohen COO, VP, Business Development
Jerry M. Anchin Vice President, Director, Prod. Dev.
Thomas J. Bohan J. Bohannon Chief Accounting Officer
Share Structure:
Market Value $0.625 Million a/o Feb 08, 2012
Shares Outstanding 56.8 Million a/o Sep 30, 2011
Float Currently Unknown
Authorized Shares Currently Unknown
Par Value 0.0001

Shareholders of Record  622  a/o Mar 31, 2011
Short Selling Data:
Short Interest 722,280 (-31.54%)
Jan 31, 2012
Significant Failures to Deliver No
Transfer Agent(s):
Corporate Stock Transfer, Inc.

Safe Harbor Statement. The above press release(s) include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Non-historical facts and/or statements contained in the above release(s) may constitute "forward-looking" statements. We caution investors that forward-looking statements prove inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions. We base any forward-looking statements on management's current expectations, which fall subject to certain factors, risks, and uncertainties that may cause actual results, events, and performance to differ materially from those referred to or implied by such statements. Moreover, actual results may differ materially from the anticipated results, depending on a variety of factors including, e.g., the following: (1) continued maintenance of favorable license arrangements; (2) success of market research identifying new product opportunities; (3) successful introduction of new products; (4) continued product innovation; (5) sales and earnings growth; (6) ability to attract and retain key personnel; and (7) general economic conditions affecting consumer spending. We caution readers not to place undue reliance on any forward-looking statements, which statements refer only to our current vantage point. We do not intend to update any of the forward-looking statements after the date of this release; thus, we shall not conform the above statements to actual results or to changes in expectations, except as the law might require.

Moderators' Position Statement and Disclaimer. This iHub Information Box, forum, and board (collectively, "Board") contains information acquired from various sources (both on and offline), which information the moderators of this Board adjusted for formatting into the Board, and presented for investors to review and analyze for themselves. No licensed brokers or investment professionals created, reviewed, revised, or approved any of the information on this Board. Each investor must complete (and finds his or her self responsible) for their own due diligence regarding the security/stock associated with this Board. Accordingly, each investor takes full responsibility for the performance and possession of any shares one purchased or might purchase. The moderator and assistant moderator(s) on this board are admittedly - and in the interest of full disclosure - rank amateurs. We therefore post only our rank amateur opinions and ideals, which is not necessarily the verified truth. We accordingly do NOT vouch for, confirm, deny, affirm, guaranty the accuracy of, or endorse any information on the Board, and we thus advise great discretion in believing or relying upon anything we post. Thus, place any reliance on what we write at YOUR own peril. YOU are the only person responsible for your opinions, conclusions, expectations, understandings, losses, gains, and/or claims pertaining in any way to the security/stock associated with this Board.


PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1166   Buy. Dusty, but did not "bite the dust." passionatebro 06/05/16 10:12:20 PM
#1165   oh well another one hits the dust. too lukin4winners 04/21/16 09:43:44 AM
#1164   VCRTQ Revoked by the SEC today. EOM flaflyersfan 04/21/16 09:37:41 AM
#1163   VCRTQ SEC Suspension for Financials / Filings delinquencies: Renee 01/22/16 09:41:50 AM
#1162   VCRTQ .001 hit starting here. lukin4winners 11/05/15 11:13:33 AM
#1161   VCRTQ has literally under 130k shares to 003 Garyst 10/26/15 03:52:48 PM
#1160   Thanks for the chart Pete! lukin4winners 10/05/15 02:15:45 PM
#1159   VCRTQ .001 couple million shares to .003 seen lukin4winners 10/05/15 02:14:24 PM
#1158   $VCRTQ Daily Chart http://stockc $Pistol Pete$ 10/05/15 02:01:53 PM
#1157   Agree. Nice to see multiple buys this Garyst 10/02/15 06:31:26 PM
#1156   More green coming next week won't take much. lukin4winners 10/02/15 04:44:43 PM
#1155   VCRTQ in the Green! Garyst 10/02/15 03:53:29 PM
#1154   I think when traders realize 17.5M top volume lukin4winners 10/02/15 03:40:10 PM
#1153   VCRTQ getting some hits now. Garyst 10/02/15 03:37:32 PM
#1152   Kinda ridiculous when it moves so easy and lukin4winners 10/02/15 03:20:55 PM
#1151   VCRTQ L2: 25k @ 0008, 10k @ 001, Garyst 10/02/15 03:16:46 PM
#1150   100k buy @.0008 and look how thin it lukin4winners 10/02/15 02:57:42 PM
#1149   Unfortunately so many do. Garyst 09/30/15 02:26:15 PM
#1148   Why buy those bloated share structure trips when lukin4winners 09/30/15 01:26:33 PM
#1147   VCRTQ under 600k to 003. Garyst 09/30/15 01:24:40 PM
#1146   The .0009s would go with any buy above lukin4winners 09/30/15 11:19:56 AM
#1145   Just needs a few hits. Garyst 09/30/15 11:13:37 AM
#1144   VCRTQ slow to start but moves easily with lukin4winners 09/30/15 10:50:43 AM
#1143   Looks like 580k to 003 which at these Garyst 09/30/15 10:38:33 AM
#1142   Won't take much to get to .0025 L2 lukin4winners 09/30/15 10:29:18 AM
#1141   VCRTQ very thin to 003 again. Garyst 09/30/15 10:27:37 AM
#1140   VCRTQ is very oversold and moves easily with lukin4winners 09/30/15 07:57:39 AM
#1139   Mayor Dilution coming!! ;-) Cubanwinner 09/29/15 04:00:32 PM
#1138   Look at VCRTQ chart went to .0058 on lukin4winners 09/29/15 10:55:03 AM
#1137   Yes. Look at HWICQ the past week from Garyst 09/29/15 10:38:10 AM
#1136   are you guys serious....? purdue pete 09/29/15 10:04:49 AM
#1135   VCRTQ a gem waiting to be discovered moves lukin4winners 09/29/15 10:03:10 AM
#1134   Agree. Garyst 09/25/15 11:09:40 AM
#1133   VCRTQ will be discovered at some point it lukin4winners 09/25/15 08:55:39 AM
#1132   Agree. This is just a tad higher Garyst 09/24/15 11:21:52 AM
#1131   And very tempting at .0008 since it went lukin4winners 09/24/15 11:06:05 AM
#1130   True. Everyday there are a few Q Garyst 09/24/15 11:03:16 AM
#1129   Holding here once traders realize how easy it lukin4winners 09/24/15 07:59:15 AM
#1128   Still holding. VCRTQ will bounce again and the Garyst 09/23/15 10:11:53 PM
#1127   Strange. Garyst 09/18/15 10:59:24 AM
#1126   Why PM action ? Weird i_like_bb_stock 09/18/15 09:25:59 AM
#1125   Agree. A 28% gain will get us Garyst 09/17/15 09:37:12 PM
#1124   Maybe scanners will come up tonight and get lukin4winners 09/17/15 09:11:50 PM
#1123   Over 1000% a month ago to 0058 from Garyst 09/17/15 09:09:13 PM
#1122   Imagine if we had some real volume. lukin4winners 09/17/15 09:03:53 PM
#1121   +28%, not a bad day. Garyst 09/17/15 08:36:57 PM
#1120   That's true it could come pretty soon. lukin4winners 09/17/15 02:57:26 PM
#1119   Correct. People always need to see a Garyst 09/17/15 02:30:36 PM
#1118   Amazingly thin a few ask hits attracts a lukin4winners 09/17/15 02:11:51 PM
#1117   VCRTQ just 630k shares to 003 now. Garyst 09/17/15 01:55:40 PM